Vol.

No.

November 03, 2023Nov 03, 2023

DOWNLOAD THE PDF

After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

Cover Story

Clinical

After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria

Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.

Suspensions, public outrage ensue as tensions over Middle East sweep through oncology
NYU Cancer Center Director Benjamin Neel suspended over social media posts

By Paul Goldberg

Guest Editorial

ACS expands lung cancer screening eligibility to ages 50-80 with 20+ pack-years
Previous guideline was 55-74 with 30+ pack years

By Robert A. Smith and William L. Dahut

Health Equity

ECOG-ACRIN renames health equity scholarships in honor of Edith Mitchell

By Matthew Bin Han Ong

Free In the Archives

The Center for the Study of Tobacco and Society: How cigarette companies targeted women through advertising

In Brief

VCU receives $6.3M+ grant for pediatric cancer research

Patrick Reagan named director of Wilmot BMT/Cellular Therapies Program

Fayez Estephan named assistant professor of medicine at GW University Cancer Center

Jennifer Vaz joins GW University Cancer Center

VUMC’s Kimryn Rathmell wins Doris Duke Foundation Paragon Award

Fatemeh Ardeshir, Andrew Srisuwananukorn receive ECOG-ACRIN Awards of Distinction

Cancer researchers Henkel Valentine, Kimiko Krieger recognized as IMPACT Fellow by National Postdoctoral Association

Dan L Duncan Comprehensive Cancer Center to open cell therapy clinical trials at Harris Health

SU2C recognized by CHOP and SITC for support of cancer research

Clinical Roundup

Phase III trial evaluating sotorasib + panitumumab: MCC patients with rare tumor mutation experienced superior PFS compared to standard of care

Phase III trial of Jemperli + chemo meets endpoint of OS in primary advanced or recurrent endometrial cancer

Report examines outcomes in children with Down syndrome and ALL

Identifying subtle differences in tumor cells can help treat endometrial cancer better

Researchers use DNA methylation and lifestyle data to estimate gastric cancer risk

“GPS” seed devices found effective in locating breast tumors in retrospective UC study

Drugs & Targets

FDA approves Keytruda + chemo for biliary tract cancer

FDA approves Loqtorz for nasopharyngeal carcinoma

AnHeart enters into exclusive license agreement with Nippon Kayaku to market and distribute taletrectinib in Japan

NCI Trials

NCI Trials for November 2023

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 41 - November 06, 2026